Premier Alternatives

Seaport Therapeutics

Boston, MA · Founded 2020 · Privately Held (backing)

Operator of a biopharmaceutical company intended to develop novel neuropsychiatric medicines in areas of patient need. Seaport Therapeutics is based in Boston, MA and was founded in 2020. It is valued at about $740 million as of Oct 2026, set by institutional fund marks. It has raised $330 million across 1 recorded round; the latest was a $226 million later-stage round in Oct 2024.

PMV mark · valuation
$740.0M
Oct 2026
Priced at
its later-stage round
Oct 2024
Total raised
$329.9M
Last round
Later Stage VC
Oct 2024

Seaport Therapeutics key facts

as of Oct 2026
  • Operator of a biopharmaceutical company intended to develop novel neuropsychiatric medicines in areas of patient need.
  • Seaport Therapeutics is valued at approximately $740.0M as of Oct 2026, per PrivateMarketView’s mark.
  • It has raised $329.9M across 1 recorded rounds; the latest was Later Stage VC ($225.9M) in Oct 2024.
  • Notable investors include General Atlantic, Goldman Sachs Asset Management, ARCH Venture Partners, Hawktail, T. Rowe Price Group — 13 tracked in total.
  • 2 institutional filers report fund marks on Seaport Therapeutics across 4 filings.
  • Seaport Therapeutics has filed 1 Form D with the SEC, most recently Oct 2024 ($225.9M sold to 33 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$740.0M

Nothing comparable since the round — shown at its later-stage round, Oct 2024 ($740.0M post-money).

set by institutional fund marksas of Oct 2026question about this number?
Free account
More of Seaport Therapeutics with a free account
  • ·The complete investor list: 13 names
  • ·Watch Seaport Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Institutional fund marks on Seaport Therapeutics

2 filers · latest Jul 2026

2 SEC-registered funds reported 4 fair-value marks on Seaport Therapeutics between May 2026 and Jul 2026. Filer-level marks and implied $/share are available to Pro members.

Unlock 4 fund marks

Membership and data by Private Market View

Every name the funds mark, next to where it trades →

Seaport Therapeutics funding rounds

1 rounds
Oct 2024Later Stage VC$225.9MSEC filing▮
Full funding history →

Seaport Therapeutics valuation

Seaport Therapeutics is valued at approximately $740 million as of Oct 2026. The figure is set by institutional fund marks. The reference point is its later-stage round in Oct 2024, at a $740 million post-money valuation.

Recent activity

In the last 90 days, Seaport Therapeutics's record added 3 institutional fund marks (latest period Jul 2026).

How much has Seaport Therapeutics raised?

Seaport Therapeutics has raised $330 million in total; 1 of its rounds is on record. The largest on record was a $226 million later-stage round in Oct 2024.

Seaport Therapeutics has filed 1 Form D with the SEC, most recently in Oct 2024 ($226 million sold to 33 investors).

Institutional holders and vehicles

2 SEC-registered funds reported 4 fair-value marks on Seaport Therapeutics between May 2026 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.

Seaport Therapeutics investors

13 investors are on record for Seaport Therapeutics, including General Atlantic, Goldman Sachs Asset Management, ARCH Venture Partners and Hawktail. By type, the record holds 4 venture capital firms and 1 family office. The later-stage round in Oct 2024 drew 33 investors.

About Seaport Therapeutics

Operator of a biopharmaceutical company intended to develop novel neuropsychiatric medicines in areas of patient need. The company's medicines offer oral bioavailability, bypassing first-pass metabolism and reducing hepatotoxicity and other side effects, enabling patients to live with neuropsychiatric disorders.

Sector
Healthcare
HQ
Boston, MA, United States
Founded
2020
Employees
47
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.